Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
Monoclonal antibody BAT123 was passively transferred into SCID mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID) to study passive antibody protection against human immunodeficiency virus type 1 (HIV-1) infection. BAT123 is specific for the third variable loop of the gp120 of HIV-1LAI. Animals were protected against subsequent infection with LAI strain, but not other virus strains, when BAT123 (1 mg/kg; 25 micrograms/mouse) was given 1 h before virus inoculation. This resulted in a peak serum concentration of 16 micrograms/mL of the antibody, which should be easily attainable in humans. In addition, postexposure protection was observed when the antibody was given within 4 h of virus inoculation. No therapeutic effect was observed, however, when BAT123 was administered after infection had been established. These results indicate that passive antibody prophylaxis against HIV-1 infection may be possible in certain clinical situations.
Gauduin
M C
MC
Aaron Diamond AIDS Research Center, New York, NY 10016, USA.
Safrit
J T
JT
Weir
R
R
Fung
M S
MS
Koup
R A
RA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology*; D015483:HIV Antibodies / Q000008:administration & dosage / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000254:growth & development / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D051379:Mice; D016513:Mice, SCID; D010446:Peptide Fragments / Q000276:immunology; D013045:Species Specificity; D013154:Spleen / Q000821:virology
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments